Only a minuscule fraction of the human genome is devoted to encoding proteins, yet proteins provide nearly 100% of the targets for currently marketed drugs. The few exceptions include antisense and RNAi oligonucleotides, some DNA-binding cancer therapeutics such as doxorubicin and cisplatin, and a chemically diverse group of antibiotics that interfere with bacterial protein biosynthesis […]
